Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies


Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Seattle , Washington , United States

Shape Therapeutics

Artificial Intelligence | Machine Learning


Shape Therapeutics | Next-generation RNA Targeted Therapies

Shape Therapeutics

Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism


Seattle , Washington , United States

The ShapeTX technology platform includes RNAskip™, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix™, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid™, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Shape Life!

 

B2B

1 to 25

N/A

N/A

Scaling Up

2018

 
 

Biotechnology

N/A

N/A

 
 

Service

Yes

Active

 
 

   Machine Learning


Biotechnology

Biotechnology


N/A

 

   Software


N/A


Machine Learning Algorithm

Machine Learning Algorithm

 
 

View All

View All AI/ML Jobs

Machine Learning Scientist

Seattle, WA

Data Engineer

Seattle, WA

Research Associate/Senior Research Associate, Technology Development

Seattle, WA

Recruiter/Senior Recruiter

Seattle, WA

Senior Project Manager, Operations

Seattle, WA

 

AI/ML Professionals

Want to work at Shape Therapeutics?

We can introduce you to the right person at Shape Therapeutics

Talk to our Talent Team

 

5

1

$112M

Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round

 
 

Date

Round

$ Raised

Investors

07/15/2021

Series B

$112M

Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management

Date : 07/15/2021

Round: Series B

$ Raised: $112M

Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management

 

Investors

Interested in researching Shape Therapeutics?

We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Shape Therapeutics

Request a Demo - Deal Souring Platform

 
David Huss


David Huss
Chief Scientific Officer

Francois Vigneault


Francois Vigneault
Co-Founder, President & CEO

Patrick Bigot


Patrick Bigot
Chief Business Officer

Will Krause


Will Krause
Vice President of Finance

Gary Fortin


Gary Fortin
Chief Operating Officer

John Suliman


John Suliman
Co-Founder

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Shape Therapeutics